dordaviprone
NDA- Indications
- H3 K27M-mutant diffuse midline glioma
Company intelligence / Profile preview
Chimerix Inc.
Durham, North Carolina, United States of Americachimerix.gcs-web.com ↗
- Ownership
- Public · CMRX
- Employees
- ~79
- Development stage
- NDA
01
Overview
FDA accepted and granted Priority Review of New Drug Application for dordaviprone as treatment for recurrent H3 K27M-mutant diffuse glioma[1]
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small moleculesOral antiviral therapeuticsImipridones
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Oncoceutics, Inc.Cantex PharmaceuticalsBARDASymBio Pharmaceuticals
04
Financials
- Market cap
- $801.1M
- Total revenue
- $57K
- Enterprise value
- $669.9M
Beyond the preview
Go deeper on Chimerix Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chimerix Inc..